Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06939764

Application of the sG8 Scale in Real-World Geriatric Oncology Patients

This study is a multicenter, prospective, observational study. The study included patients aged 65 and older with solid tumors requiring systemic anti-tumor therapy. All patients underwent screening using the sG8 scale before the start of treatment, followed by routine treatment based on a plan developed through clinician decision-making. The study did not intervene in any way with the patients' diagnosis and treatment, and relevant clinical data during the treatment process were recorded accurately for follow-up patients. Study data were obtained from the electronic medical record databases and hospital information systems of multiple centers, including Sichuan Cancer Hospital. Patient clinicopathological features, pathological diagnoses, clinical stages, previous treatment histories, as well as anti-tumor treatment regimens after patient enrollment, drug dosages per cycle, treatment start times, incidence and grades of adverse events (AEs), and tumor response were extracted and collected from the medical records. All data were entered, managed, quality-controlled, exported, and analyzed through a real-world data management platform (RWDMP).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 65 years or older.
  • Patients with confirmed malignant tumors based on definitive pathological data.
  • Patients who are assessed by clinicians to have indications for systemic anti-tumor therapy.
  • Patients with a survival time greater than 12 weeks.

Exclusion criteria

  • Patients who do not meet the above inclusion criteria or are considered unsuitable for this study by the investigator due to other circumstances.
  • Patients who are unwilling to cooperate in completing the sG8 scale assessment.
  • Patients who do not understand the content of this study or are unwilling to participate.

Treatment and study plan

Geriatric Screening using the sG8 scale

Other

Geriatric screening using the sG8 scale

Primary outcomes

  1. The incidence of unplanned treatment delays and treatment interruptions

    Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months

    The incidence of unplanned treatment delays and treatment interruptions

Secondary outcomes

  1. TRAE

    Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months

    Number and percentage of patents with treatment-related adverse events assessed by CTCAE v5.0.

  2. ORR

    Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months

    the sum percentage of participants with CR and PR assessed by RECIST v1.1 criteria every 8-12 weeks.

  3. PFS

    Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months.

    Systemic Progression-Free Survival assessed by the investigators using RECIST V1.1.

Other outcomes

  1. OS

    Time frame: From date receiving anti-tumor therapy after the first screening assessment until date of death or the end of study, whichever came first, assessed up to 12 months

    Overall survival

Sponsors and collaborators

Lead sponsor

Sichuan Cancer Hospital and Research Institute

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Apr 23, 2025
Registry last updated
Apr 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.